Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 7/F, K11 Atelier, 728 King's Road 000000 |
Tel: | N/A |
Website: | https://ir.prenetics.com |
IR: | See website |
Key People | ||
Sheng Wu Yeung Chairman of the Board, Chief Executive Officer | Hoi Chun Lo Chief Financial Officer | Avrom Boris Lasarow Chief Executive Officer of EMEA |
Yung Ho Wong Chief Technology Officer | Chi Hung Tzang Chief Scientific Officer | Wu Po Ma Chief R&D Officer |
Shih-Chang Ong Chief Medical Officer | Senthil Sundaram Chief Clinical Officer |
Business Overview |
Prenetics Global Ltd is a company mainly engaged in the diagnostics and genetic testing business. The Company operates its business through two segments. The Diagnostics segment is engaged in the provision of COVID-19 testing services and operation testing laboratories. The Segment is also engaged in the development of health monitoring systems. The Prevention segment is engaged in the provision of genetics testing services to individuals and corporate entities. |
Financial Overview |
For the fiscal year ended 31 December 2023, Prenetics Global Ltd revenues increased 65% to $21.7M. Net loss before extraordinary items decreased 76% to $54.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Share-based payment on listing decrease from $89.5M (expense) to $0K, Fair value loss on preference shares lia decrease from $60.1M (expense) to |
Employees: | 800 as of Mar 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1.89M as of Dec 31, 2023 |
Annual revenue (TTM): | $21.74M as of Dec 31, 2023 |
EBITDA (TTM): | -$41.34M as of Dec 31, 2023 |
Net annual income (TTM): | -$54.35M as of Dec 31, 2023 |
Free cash flow (TTM): | N/A |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 12,205,200 as of Dec 31, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |